TransMedics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
April 01, 2024 at 02:02 am IST
Share
TransMedics Group, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 96.85 million compared to USD 41.55 million a year ago. Net income was USD 12.2 million compared to net loss of USD 2.64 million a year ago.
Basic earnings per share from continuing operations was USD 0.37 compared to basic loss per share from continuing operations of USD 0.08 a year ago. Diluted earnings per share from continuing operations was USD 0.35 compared to diluted loss per share from continuing operations of USD 0.08 a year ago.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.